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ABSTRACT	  	  	  The	  pharmaceutical	  market	  is	  considered	  as	  one	  of	  the	  most	  regulated	  in	  the	  developed	  world.	  Still,	  we	  see	  an	  ongoing	  trend	  with	  increasing	  global	  pharmaceutical	  spending	  and	  lack	  of	  breakthroughs	  in	  life	  science	  discoveries.	  The	  reasons	  are	  different	  depending	  on	  which	  source	  you	  rely	  on.	  The	  payers,	  the	  originators	  and	  the	  drug	  agencies	  are	  arguably	  the	  key	  players	  in	  this	  market.	  This	  study	  examined	  the	  current	  status	  of	  the	  industry,	  how	  the	  market	  rules	  have	  changed	  and	  how	  the	  absence	  of	  isomorphism	  between	  the	  world’s	  biggest	  drug	  agency,	  the	  U.S.	  Food	  and	  Drug	  Administration,	  and	  the	  pharmaceutical	  companies	  may	  be	  a	  source	  of	  the	  problems.	  The	  employees	  interviewed	  at	  the	  agency	  partly	  explained	  their	  views,	  which	  mostly	  were	  consistent	  with	  the	  current	  limited	  literature.	  In	  conclusion,	  the	  formal	  structure	  of	  an	  independent	  organization	  limits	  the	  isomorphism	  with	  the	  environment,	  and	  thereby	  the	  success	  for	  cost	  containment	  and	  drug	  innovation	  management.	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Table	  1.	  Definition	  and	  description	  of	  abbreviations	  and	  terms.	  
Abbreviation/Term	   Description	  
Big	  Pharma	  
	  
The	  major	  pharmaceutical	  companies.	  
Blockbuster	   A	  drug	  that	  generates	  more	  than	  one	  billion	  dollar/year	  in	  revenue	  for	  its	  owner.	  
EMA	   European	  Medicines	  Agency.	  European	  Union’s	  drug	  agency.	  
EPB	   External	  Price	  Benchmarking:	  The	  price	  of	  a	  drug	  in	  a	  country	  is	  decided	  on	  the	  price	  of	  the	  same	  drug	  in	  a	  group	  of	  other	  countries.	  
FDA	   The	  Food	  and	  Drug	  Administration.	  The	  national	  drug	  agency	  of	  USA.	  
Generic	  Drug	   A	  drug	  product	  that	  is	  comparable	  to	  brand/reference	  listed	  drug	  product	  in	  dosage	  form,	  strength,	  route	  of	  administration,	  quality	  and	  performance	  characteristics,	  and	  intended	  use.	  
IRP	   Internal	  Reference	  Pricing:	  A	  drug’s	  price	  in	  a	  country	  depends	  on	  the	  price	  of	  similar,	  potentially	  already	  off-­‐patent	  drugs	  in	  the	  same	  country.	  
Me-­‐too	  Drug	  
	  
A	  drug	  that	  is	  structurally	  similar	  to	  already	  known	  drugs.	  Only	  minor	  differences	  in	  most	  aspects.	  
NDA	   New	  Drug	  Application.	  A	  formal	  application	  where	  drug	  sponsors	  propose	  that	  the	  FDA	  approve	  a	  new	  pharmaceutical	  market	  entry.	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Abbreviation/Term	   Description	  
NME	   New	  Molecular	  Entity.	  A	  product	  that	  contains	  active	  moieties	  that	  have	  not	  been	  approved	  by	  the	  drug	  agency	  previously.	  
Orphan	  Drug	  
	  
Drugs	  for	  life-­‐threatening	  or	  very	  serious	  diseases	  or	  disorders	  that	  are	  rare	  in	  prevalence	  and	  incidence.	  
PMDA	   Pharmaceuticals	  and	  Medical	  Devices	  Agency.	  Japan’s	  drug	  regulatory	  agency.	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Introduction	  
Background	  The	  pharmaceutical	  market	  is	  one	  of	  the	  most	  regulated	  in	  the	  developed	  world	  (Garattini,	  Cornago	  and	  De	  Compadri,	  2007).	  The	  governments	  have	  certain	  objectives	  such	  as	  maintaining	  and	  improving	  the	  health	  of	  their	  citizens	  through	  effective	  drugs	  in	  the	  domestic	  market	  and	  correct	  usage	  and	  information	  regarding	  the	  medications	  with	  marketing	  authorization.	  Although	  pharmaceuticals	  are	  essential	  for	  the	  healthcare	  system	  in	  any	  given	  society,	  the	  increasing	  expenditures	  have	  become	  a	  great	  issue	  (Mossialos,	  Mrazek	  and	  Walley,	  2004),	  whether	  the	  payer	  is	  the	  government	  or	  a	  private	  insurer.	  As	  the	  world	  is	  facing	  an	  aging	  population	  (NIA,	  2011)	  and	  the	  fact	  that	  people	  over	  age	  65	  are	  more	  likely	  to	  be	  regular	  prescription	  users	  than	  their	  younger	  counterpart	  (Lehrer,	  et	  al.,	  2000),	  a	  highly	  complex	  challenge	  has	  developed.	  	  To	  manage	  the	  rising	  pharmaceutical	  expenditure,	  some	  health	  insurance	  systems	  apply	  the	  idea	  of	  pricing	  and	  reimbursement	  regulation.	  This	  approach	  is	  different	  depending	  on	  the	  country,	  but	  in	  general	  three	  forms	  exist:	  Internal	  Reference	  Pricing	  (IRP);	  External	  Price	  Benchmarking	  (EPB);	  and	  Value-­‐based	  pricing	  (see	  table	  1	  for	  a	  summary	  of	  abbreviations	  and	  terms	  used	  in	  the	  text).	  They	  are	  common	  in	  Western	  Europe	  where	  17%	  of	  the	  pharmaceutical	  industry’s	  revenues	  were	  generated	  in	  2011	  (IFPMA,	  2012).	  World’s	  biggest	  pharmaceutical	  market,	  USA,	  had	  34%	  of	  the	  industry’s	  2011	  revenues.	  It	  is	  considered	  as	  a	  region	  with	  market-­‐based	  pricing.	  However,	  managed	  care	  organizations	  (Slovick,	  2011)	  as	  well	  as	  public	  social	  assistance	  programs	  (Friederiszick,	  et	  al.,	  2009)	  promote	  the	  use	  of	  cheaper	  options	  instead	  of	  the	  most	  expensive	  and	  novel	  drugs,	  as	  well	  as	  price	  negotiations,	  through	  different	  strategies.	  Thus	  the	  free	  pricing	  is	  to	  some	  degree	  regulated	  if	  the	  pharmaceutical	  company	  wants	  to	  be	  entitled	  reimbursement	  for	  its	  product.	  	  This	  strategy	  has	  been	  quite	  successful	  which	  we	  will	  see	  in	  the	  next	  chapters,	  as	  expensive	  patented	  drugs	  in	  the	  same	  therapeutic	  cluster	  as	  generic	  substitutes	  are	  rarely	  the	  first	  choice	  to	  be	  prescribed	  due	  to	  they	  are	  not	  covered	  or	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prioritized	  in	  most	  health	  insurance	  systems.	  But	  the	  problem	  has	  yet	  not	  been	  solved.	  	  What	  can	  have	  caused	  this	  is	  highly	  debatable	  depending	  on	  the	  source	  you	  read,	  as	  the	  pharmaceutical	  industry,	  with	  astonishing	  annual	  revenues	  has	  several	  different	  key	  players	  that	  influence	  the	  market.	  	  	  	  
Research	  Problem	  The	  increasing	  expenditure	  issue	  the	  market	  is	  facing	  and	  the	  lack	  of	  breakthroughs	  in	  life	  science	  discoveries	  are	  signs	  of	  mismanagement	  from	  the	  stakeholders’	  part.	  It	  is	  impossible	  to	  blame	  one	  group	  or	  organization.	  At	  the	  same	  time,	  the	  need	  for	  pharmaceuticals	  shows	  no	  sign	  of	  decline	  –	  rather	  steady	  increase.	  	  	  The	  changing	  business	  environment	  the	  companies	  have	  experienced	  as	  a	  reaction	  from	  the	  payers	  less	  willingness	  to	  reimburse	  and	  fewer	  novel	  drugs,	  have	  made	  them	  changing	  focus	  in	  their	  drug	  development	  programs,	  as	  the	  pharmaceutical	  industry,	  like	  any	  other	  industry,	  is	  profit	  driven.	  This	  has	  eventually	  created	  other	  challenges,	  such	  as	  drug	  shortage,	  less	  accessibility	  and	  extremely	  expensive	  drugs	  not	  covered	  by	  payers.	  This	  brings	  up	  the	  discussion	  on	  how	  a	  drug	  regulatory	  agency,	  which	  has	  the	  mission	  to	  oversee	  these	  problems,	  in	  such	  a	  traditional	  and	  innovative	  industry,	  have	  allowed	  this	  to	  evolve?	  Can	  this	  be	  the	  result	  of	  an	  environment	  where	  the	  companies	  have	  not	  been	  regulated	  enough?	  Is	  this	  a	  proof	  of	  lack	  of	  ability	  from	  the	  regulatory	  agencies	  to	  incorporate	  structural	  elements	  isomorphic	  with	  the	  environment?	  	  	  	  	  	  
Key	  Question	  This	  Work	  Can	  Address	  Has	  the	  formal	  structure	  of	  the	  U.S.	  Food	  and	  Drug	  Administration	  (FDA),	  the	  world’s	  biggest	  drug	  agency,	  limited	  it	  from	  influencing	  the	  challenges	  in	  the	  pricing	  and	  reimbursement	  of	  pharmaceuticals	  and	  drug	  innovation	  character?	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Theory	  Background	  
The	  Institutionalization	  Organizations	  making	  up	  a	  specific	  field	  have	  a	  tendency	  to	  be	  the	  same	  in	  how	  they	  look	  and	  act	  (Miles,	  2012).	  The	  theory	  behind	  this	  has	  the	  concept	  that	  in	  order	  to	  be	  accepted,	  organizational	  structures	  and	  processes	  search	  for	  meaning	  and	  stability	  in	  their	  own	  right.	  This	  is	  more	  prioritized	  than	  improving	  effectiveness	  and	  efficiency	  of	  the	  organization.	  Over	  time	  the	  structures	  and	  practices	  become	  more	  and	  more	  homogenous	  in	  the	  organization.	  	  	  	  Institutions	  in	  general	  form	  are	  essential	  components	  in	  the	  environment.	  The	  regulative,	  but	  also	  normative	  and	  cognitive	  structures	  and	  activities	  they	  have,	  create	  some	  kind	  of	  stability	  and	  meaning	  for	  social	  behavior,	  as	  mentioned	  by	  Scott	  (1995,	  p.	  33).	  The	  institutions	  laws,	  regulations,	  culture	  and	  ethics	  are	  some	  examples.	  To	  become	  legitimate	  by	  internal	  and	  external	  stakeholders,	  the	  organization’s	  actions	  must	  be	  consistent	  with	  current	  norms,	  rules	  and	  beliefs	  (Miles,	  2012,	  p.	  146).	  The	  more	  they	  submit	  to	  the	  social	  norms,	  the	  more	  they	  earn	  the	  legitimacy	  to	  continue	  with	  their	  operations	  by	  increased	  resources	  and	  survival	  capabilities.	  Powell	  and	  DiMaggio	  (1991)	  emphasize	  how	  the	  institutionalized	  activities	  occur	  on	  interorganizational	  level	  when	  industry	  alliances	  and	  expectations	  from	  society	  define	  the	  social	  and	  expected	  organizational	  behavior,	  hence	  forcing	  organizations	  to	  look	  and	  act	  the	  same.	  	  Heugens	  and	  Lander	  (2009),	  discuss	  two	  disputes	  among	  institutional	  theorists,	  where	  the	  first	  one	  examines	  the	  supremacy	  the	  structure	  itself	  has	  over	  the	  agency.	  They	  ask	  the	  question	  whether	  it	  is	  the	  macro	  societal	  forces	  or	  the	  organization’s	  actions	  that	  are	  behind	  the	  emergence	  of	  organizational	  structures	  and	  processes.	  The	  second	  dispute	  covers	  the	  influence	  of	  conformity	  on	  organizational	  structure.	  	  	  Being	  quite	  accepted	  in	  general,	  the	  institutional	  theory	  has	  also	  been	  criticized	  from	  some	  points.	  Kraatz	  and	  Zajac	  (1996)	  had	  limited	  success	  in	  finding	  evidence	  that	  supported	  the	  constraint	  of	  legitimacy.	  Also,	  high-­‐status	  players	  seem	  to	  be	  able	  to	  deviate	  from	  the	  norm	  thanks	  to	  reputational	  capital,	  which	  is	  not	  the	  case	  for	  middle-­‐status	  and	  low-­‐status	  players	  (Phillips	  and	  Zuckerman,	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2001).	  	  Further,	  some	  critics	  mention	  that	  the	  mechanisms	  underlying	  institutionalization	  have	  yet	  not	  been	  investigated.	  The	  effects	  are	  clearly	  examined,	  but	  with	  the	  absence	  of	  the	  processes	  that	  result	  in	  organizations	  becoming	  institutionalized,	  we	  may	  see	  organizations	  as	  “black	  boxes”	  without	  seeing	  the	  value	  inside	  of	  them	  (Phillips,	  Lawrence	  and	  Hardy,	  2004).	  	  
	  
Lack	  of	  Functioning	  Isomorphism	  Meyer	  and	  Rowan	  (1977,	  p.	  342)	  explain	  that	  when	  markets	  expand,	  the	  complexity	  regarding	  relational	  networks	  increases.	  The	  size	  and	  technology	  creates	  a	  need	  for	  coordination,	  and	  organizations	  with	  rationalized	  formal	  structures.	  A	  bureaucratic	  structure,	  such	  as	  the	  FDA,	  is	  thought	  to	  be	  the	  most	  effective	  alternative	  to	  standardize	  and	  control	  subunits,	  which	  is	  true	  in	  the	  regulated	  pharmaceutical	  market.	  Further,	  to	  not	  lose	  their	  legitimacy,	  such	  organizations	  have	  to	  institutionalize	  certain	  elements	  as	  they	  are	  socially	  expected	  (Meyer	  &	  Rowan,	  1977,	  p.	  344),	  which	  was	  also	  mentioned	  in	  previous	  section.	  In	  the	  case	  of	  the	  FDA	  or	  any	  drug	  agency,	  it	  is	  to	  protect	  the	  public	  health	  by	  taking	  responsibility	  of	  the	  safety,	  efficacy	  and	  security	  of	  drugs	  in	  the	  market.	  While	  the	  safety	  and	  efficacy	  responsibility	  are	  highly	  institutionalized,	  the	  issue	  with	  cost	  containment	  has	  been	  neglected.	  One	  may	  argue	  that	  politicians	  or	  other	  organizations	  decide	  the	  financial	  part,	  but	  it	  cannot	  be	  denied	  that	  the	  FDA	  has	  high	  influence	  in	  the	  financial	  aspect	  of	  a	  drug	  e.g.	  review	  time	  before	  drug	  approval	  and	  exclusivity	  rights.	  A	  future	  area	  of	  significance	  could	  be	  cost-­‐effectiveness.	  This	  area	  has	  grown	  in	  importance	  to	  contain	  a	  healthy	  pharmaceutical	  spending.	  Meyer	  and	  Rowan	  (p.	  345)	  describe	  this	  phenomenon	  as	  a	  building	  block	  that	  an	  organization	  must	  incorporate	  to	  avoid	  illegitimacy.	  The	  authors	  continue	  to	  argue	  that	  the	  absence	  of	  this	  building	  block	  being	  incorporated	  in	  the	  organization	  makes	  it	  difficult	  to	  manage	  interdependencies.	  Consequently,	  the	  lack	  of	  exchange	  creates	  a	  difficult	  environment	  to	  operate	  successfully	  in.	  This	  could	  be	  one	  of	  the	  reasons	  behind	  the	  challenge	  of	  excessive	  pharmaceutical	  spending.	  Powell	  and	  DiMaggio	  (1991,	  p.	  66)	  come	  with	  the	  same	  explanation:	  the	  organizational	  characteristics	  must	  adapt	  in	  the	  direction	  of	  environmental	  characteristics	  to	  survive	  and	  become	  successful.	  There	  are	  three	  mechanisms	  through	  which	  this	  isomorphic	  change	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can	  occur:	  coercive,	  mimetic	  and	  normative	  (Powell	  and	  DiMaggio,	  1991,	  p.	  67-­‐74).	  	  	  
Coercive	  Isomorphism	  The	  coercive	  isomorphism	  is	  the	  result	  of	  formal	  and	  informal	  pressures	  organizations	  experience	  by	  other	  organizations,	  which	  they	  are	  dependent	  on,	  and	  also	  the	  cultural	  expectations	  in	  the	  society	  they	  operate.	  We	  see	  this	  in	  our	  case	  where	  the	  FDA	  regulates	  organizations	  (i.e.	  pharmaceutical	  companies),	  and	  the	  changes	  they	  make	  (e.g.	  new	  guidelines	  in	  how	  to	  perform	  clinical	  trials)	  are	  a	  direct	  response	  to	  the	  drug	  agency’s	  mandate.	  Meyer	  and	  Rowan	  (1977)	  have	  repeatedly	  stressed	  how	  organizations	  are	  increasingly	  homogenous	  in	  certain	  domains	  and	  organized	  around	  the	  rituals	  of	  conformity	  to	  wider	  institutions.	  This	  is	  not	  unique	  for	  the	  governmental	  arena.	  Sedlak	  (1981)	  describes	  how	  United	  Charities	  (an	  American	  charity	  trust),	  became	  homogenized	  the	  structures,	  methods	  and	  philosophies	  in	  order	  to	  adapt	  to	  the	  social	  service	  agencies	  that	  depended	  upon	  it.	  Also,	  the	  bigger	  size	  and	  scope	  of	  corporations	  make	  subsidiaries	  subject	  to	  standardized	  reporting	  mechanisms	  (Coser,	  Kadushin	  and	  Powell,	  1982).	  	  	  
Mimetic	  Isomorphism	  	  Uncertainty	  is	  a	  force	  that	  encourages	  imitation.	  Operating	  in	  an	  environment	  that	  requires	  ambiguous	  goals	  in	  order	  to	  success,	  organizations	  tend	  to	  model	  themselves	  on	  other	  organizations	  (Powell	  and	  DiMaggio,	  1991,	  p.	  69).	  This	  mimetic	  response	  to	  uncertainty	  is	  a	  viable	  solution	  with	  little	  expense.	  The	  modeled	  organization	  is	  not	  always	  aware	  of	  the	  modeling	  and	  may	  sometimes	  not	  want	  to	  be	  copied.	  Westney	  (1987)	  gives	  an	  example	  of	  imitation	  when	  Japan	  in	  the	  late	  nineteenth	  century	  started	  its	  modernization	  by	  modeling	  new	  governmental	  initiatives	  on	  successful	  Western	  prototypes.	  This	  process,	  where	  the	  Japanese	  sent	  officers	  to	  study	  different	  institutions	  in	  different	  Western	  countries	  is	  today	  ironically	  used	  by	  American	  corporations	  in	  their	  efforts	  to	  implement	  Japanese	  models	  in	  order	  to	  improve	  productivity	  and	  personnel	  problems	  in	  their	  own	  firms.	  These	  developments	  also	  enhance	  their	  legitimacy	  as	  they	  try	  to	  adopt	  these	  “innovations”.	  And	  the	  more	  reputable	  organization,	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the	  more	  pressure	  felt	  to	  provide	  the	  programs	  other	  organizations	  offer.	  This	  shows	  how	  a	  skilled	  labor	  force	  or	  a	  broad	  customer	  base	  can	  lead	  to	  mimetic	  isomorphism.	  	  	  
Normative	  Isomorphism	  The	  last	  source	  of	  isomorphic	  organizational	  change	  is	  the	  normative.	  It	  stems	  mainly	  from	  professionalization.	  Professionals	  in	  general	  do	  have	  to	  compromise	  with	  nonprofessional	  regulators,	  clients,	  etc.	  Their	  complete	  futures	  are	  bound	  up	  with	  the	  fortunes	  of	  the	  organizations	  they	  are	  hired	  at	  (Hall,	  1968).	  The	  professional	  power	  is	  assigned	  both	  by	  the	  state	  and	  the	  activities	  of	  the	  professions.	  Two	  mechanisms	  behind	  professionalization	  are	  of	  importance	  for	  the	  isomorphism.	  First	  one	  is	  the	  formal	  education	  and	  legitimation,	  a	  product	  by	  university	  specialists.	  Second	  one	  is	  the	  emergence	  and	  elaboration	  of	  professional	  networks,	  that	  cover	  organizations	  and	  across	  where	  new	  models	  can	  diffuse	  rapidly	  (Perrow,	  1974).	  The	  filtering	  of	  personnel	  is	  an	  important	  source	  for	  normative	  isomorphism.	  This	  hiring	  process	  is	  highly	  selective	  and	  those	  who	  make	  it	  to	  the	  top	  are	  quite	  indistinguishable.	  An	  example	  is	  the	  findings	  of	  March	  and	  March	  (1977):	  All	  individuals	  that	  attained	  the	  position	  of	  school	  superintendent	  in	  Wisconsin,	  USA,	  had	  a	  background	  and	  orientation	  that	  made	  them	  inseparable	  regarding	  making	  further	  career	  advancement	  random	  and	  unpredictable.	  The	  same	  was	  the	  case	  for	  Fortune	  500	  board	  members	  studied	  by	  Hirsch	  and	  Whisler	  (1982).	  There	  seems	  to	  be	  an	  anticipation	  for	  individuals	  in	  any	  given	  organizational	  field	  to	  undergo	  a	  certain	  socialization	  that	  corresponds	  to	  common	  expectations	  regarding	  their	  personal	  behavior,	  appropriate	  style	  of	  dress,	  vocabularies	  used,	  etcetera	  (Cicourel	  1970;	  Williamson	  1975).	  The	  recruitment	  of	  similar	  type	  of	  people,	  tend	  to	  result	  in	  viewing	  problems	  from	  the	  same	  point	  of	  view,	  approaching	  decisions	  in	  similar	  way,	  and	  see	  the	  same	  policies	  (Kanter,	  1977).	  Professionalization	  of	  management	  contributes	  to	  a	  commonly	  recognized	  hierarchy	  of	  status.	  With	  the	  designation	  of	  few	  large	  firms	  acting	  as	  key	  bargaining	  agents,	  and	  government	  recognition	  of	  these	  key	  organizations,	  give	  these	  actors	  legitimacy	  and	  visibility,	  which	  competing	  firms	  try	  to	  imitate	  with	  the	  hope	  of	  obtaining	  similar	  rewards	  (Useem,	  1979).	  Thus,	  organizational	  fields	  with	  a	  large	  professionally	  trained	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labor	  force	  are	  primarily	  driven	  by	  status	  competition.	  Lee	  (1971:51),	  for	  example	  noticed	  how	  hospital	  administrators	  were	  not	  concerned	  about	  efficient	  use	  of	  resources,	  but	  interested	  with	  status	  competition	  and	  parity	  in	  prestige.	  	  	  	  	  	  	  Indeed	  the	  FDA	  has	  done	  major	  progress	  to	  become	  isomorphic,	  but	  in	  the	  rapid	  changing	  pharmaceutical	  environment,	  wrong	  elements	  which	  are	  legitimated	  externally	  may	  have	  been	  rationalized	  i.e.	  safety	  and	  efficacy	  area	  of	  drugs,	  rather	  than	  efficiency	  in	  general	  where	  cost-­‐effectiveness	  of	  drugs	  is	  an	  example.	  
	  
The	  Current	  Status	  in	  the	  Pharmaceutical	  Industry	  
The	  Originators	  Looking	  specifically	  at	  the	  industry,	  we	  can	  divide	  the	  companies	  involved	  into	  two	  main	  subsectors:	  originators	  and	  generic	  producers.	  While	  originators	  products	  are	  developed	  through	  extensive	  research	  &	  development	  (R&D),	  clinical	  and	  sometimes	  post-­‐marketing	  trials,	  and	  patented	  to	  protect	  the	  company’s	  exclusive	  rights,	  the	  generic	  producers	  products	  are	  cheaper	  identical	  copies	  of	  originators	  drugs	  when	  they	  go	  off-­‐patent	  (SelectUSA,	  2013).	  	  	  It	  is	  the	  originators	  that	  innovate	  new	  drugs	  for	  the	  market.	  Figures	  differ	  depending	  on	  source,	  but	  in	  general	  it	  takes	  13-­‐15	  years	  (DiMasi,	  1995)	  and	  costs	  an	  average	  of	  $1	  billion	  to	  develop	  a	  novel	  drug	  (DiMasi,	  Hansen	  and	  Grabowski,	  2003).	  	  Figure	  1	  shows	  the	  timeline	  from	  the	  discovery	  of	  one	  potential	  drug	  candidate	  out	  of	  5,000-­‐10,000	  tested	  compounds,	  to	  product	  launch.	  As	  a	  reward	  the	  company	  behind	  a	  novel	  drug	  can	  claim	  a	  much	  higher	  market	  price,	  so	  that	  they	  can	  compensate	  for	  the	  time	  and	  R&D-­‐investments	  they	  have	  made.	  	  However,	  the	  higher	  price	  is	  for	  a	  limited	  period	  of	  time.	  In	  the	  USA	  and	  EU	  the	  patent	  time	  is	  20	  years	  (subject	  to	  change)	  from	  the	  date	  of	  filing	  (FDA,	  2012	  and	  EGA,	  2004)	  and	  as	  it	  expires	  any	  competitor	  is	  free	  to	  manufacture	  the	  same	  drug.	  This	  has,	  as	  we	  mentioned	  earlier,	  giving	  rise	  to	  pricing	  and	  reimbursement	  regulation	  to	  manage	  the	  staggering	  pharmaceutical	  costs	  for	  the	  payers.	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Figure	  1.	  Timeline	  from	  discovery	  to	  product	  launch	  for	  a	  successful	  drug	  (source:	  GlaxoSmithKline	  annual	  report	  2012,	  p.	  34).	  
	  
	  
The	  Payers	  Although	  the	  health	  insurance	  systems	  in	  the	  western	  European	  countries	  may	  differ,	  they	  are	  in	  general	  well	  developed	  and	  cover	  a	  great	  part	  of	  the	  citizens’	  pharmaceutical	  costs	  (Garattini,	  Cornago	  and	  De	  Compadri,	  2007).	  The	  case	  is	  different	  in	  the	  USA	  where	  private	  health	  insurers	  cover	  differently	  (Berndt	  and	  Newhouse,	  2010).	  As	  the	  pharmaceutical	  spending	  continues	  to	  grow	  worldwide	  (IFPMA,	  2012),	  regulations	  are	  needed	  for	  the	  expenditure	  containment.	  As	  discussed	  earlier,	  reference	  pricing	  has	  been	  an	  effective	  way.	  At	  the	  same	  time,	  we	  do	  not	  see	  a	  decline	  in	  total	  expenditures.	  An	  aging	  world	  population	  and	  developing	  countries	  building	  well-­‐functioning	  healthcare	  systems	  are	  two	  of	  the	  reasons.	  But	  the	  numbers	  of	  new	  drugs	  approved,	  which	  are	  an	  important	  factor	  in	  the	  increasing	  global	  spending,	  have	  declined.	  In	  fact,	  in	  2012,	  the	  FDA	  approved	  39	  new	  drugs	  (including	  biologics),	  a	  16	  year	  high	  (C&EN,	  2013).	  Also,	  we	  do	  need	  to	  include	  that	  the	  recent	  financial	  crisis	  has	  had	  a	  negative	  impact	  on	  the	  healthcare	  system	  and	  as	  a	  consequence	  on	  the	  pharmaceutical	  sector’s	  revenue	  in	  the	  western	  world.	  Traditionally,	  the	  pharmaceutical	  sector	  has	  been	  less	  exposed	  during	  economic	  crisis,	  but	  is	  in	  this	  case	  not	  an	  exception	  (Behner,	  et	  al.,	  2009).	  This	  does	  however	  not	  change	  the	  fact	  that	  pharmaceuticals	  are	  not	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just	  another	  typical	  product	  and	  dependent	  on	  the	  economic	  situation.	  The	  inelastic	  demand	  will	  continue	  to	  grow,	  as	  people	  need	  to	  take	  their	  medication	  continuously.	  Because	  of	  the	  stricter	  pricing	  and	  reimbursement	  are	  set	  by	  national	  regulators	  where	  the	  expert	  panel	  views	  could	  be	  different,	  and	  the	  R&D	  activities	  are	  performed	  on	  a	  global	  level;	  the	  final	  outcome	  for	  a	  pharmaceutical	  product	  today	  is	  more	  unpredictable.	  The	  pricing	  and	  reimbursement	  model	  in	  each	  market	  of	  interest	  needs	  to	  be	  reviewed,	  as	  a	  novel	  drug	  could	  become	  a	  huge	  success	  in	  one	  country,	  but	  downgraded	  somewhere	  else.	  And	  this	  certainly	  affects	  the	  incentives	  of	  innovation.	  	  	  	  	  
The	  Drug	  Agencies	  To	  reach	  the	  market,	  a	  potential	  chemical	  or	  biological	  compound	  must	  be	  reviewed	  by	  drug	  agencies.	  Currently	  there	  are	  three	  national	  drug	  agencies	  of	  importance:	  The	  Food	  and	  Drug	  Administration	  (FDA),	  which	  is	  based	  in	  the	  USA;	  European	  Medicines	  Agency	  (EMA),	  the	  EU	  version	  of	  the	  FDA;	  Pharmaceuticals	  and	  Medical	  Agency	  (PAMD),	  the	  drug	  agency	  of	  Japan.	  The	  reason	  why	  these	  three	  authorities	  are	  the	  most	  influential	  ones	  is	  because	  of	  the	  fact	  that	  they	  together	  regulate	  the	  drug	  safety	  and	  efficacy	  aspect	  for	  markets	  that	  have	  a	  63%	  share	  of	  the	  total	  pharmaceutical	  spending	  in	  the	  world	  (IFMPA,	  2012).	  We	  will	  mainly	  be	  focusing	  on	  the	  FDA	  as	  the	  USA	  is	  the	  biggest	  pharmaceutical	  market,	  the	  FDA	  the	  oldest	  authority	  of	  the	  three	  mentioned,	  and	  the	  decisions	  made	  by	  them	  highly	  affect	  other	  markets.	  The	  agency	  has	  approximately	  14,648	  employees	  in	  2013,	  where	  10,534	  are	  in	  the	  drug	  related	  field	  (FDA,	  2013).	  The	  requested	  budget	  for	  2013	  was	  almost	  $4.5	  billion	  (FDA,	  2013).	  The	  expertise	  area	  covers	  all	  aspects	  of	  a	  drug’s	  safety	  and	  efficacy.	  	  
Changing	  Trend	  The	  major	  pharmaceutical	  companies,	  commonly	  known	  as	  Big	  Pharma,	  have	  the	  major	  share	  of	  the	  market.	  Their	  countries	  of	  origin	  vary,	  but	  are	  mostly	  localized	  to	  the	  western	  world.	  Some	  critics	  have	  compared	  the	  pharmaceutical	  market	  as	  an	  oligopoly	  and	  the	  reason	  for	  this	  can	  be	  referred	  to	  the	  huge	  costs,	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the	  need	  for	  expertise	  in	  different	  fields,	  the	  time	  to	  develop	  new	  drugs,	  but	  also	  to	  mergers	  &	  acquisitions	  (M&A)	  the	  industry	  has	  experienced	  where	  multinational	  firms	  such	  as	  Wyeth	  and	  Schering-­‐Plough	  have	  been	  acquired	  from	  different	  competitors	  and	  mergers	  have	  created	  AstraZeneca	  and	  Sanofi.	  This	  business	  condition	  makes	  it	  quite	  hard,	  if	  not	  impossible,	  for	  smaller	  companies	  to	  survive.	  	  The	  ten	  biggest	  pharmaceutical	  companies	  in	  the	  world	  are	  listed	  in	  table	  2.	  Their	  accumulated	  revenues	  in	  2012	  were	  approximately	  $414.7	  billion.	  In	  this	  group	  we	  can	  see	  that	  the	  company	  that	  spent	  least	  percentage	  of	  annual	  revenues	  on	  R&D	  was	  Abbott	  Laboratories	  with	  10.5%,	  while	  Johnson	  &	  Johnson	  spent	  most	  with	  21.3%	  of	  its	  annual	  revenues.	  	  	  	  












R&D	  costs	  (%	  of	  
annual	  
revenues)	  
Johnson	  &	  Johnson	  
(USA)	  
67.2	  (25.4)*	   13.8	   7.7	  (5.4)*	   11.5	  (21.3)*	  
Pfizer	  
(USA)	  
59.0	   24.2	   7.9	   13.4	  
Novartis	  
(Swtitzerland)	  
56.7	   11.5	   9.3	   16.4	  
Roche	  
(Swtizerland)	  
47.8	   14.8	   8.9	   18.6	  
Merck	  
(USA)	  
47.3	   8.74	   7.9	   16.7	  
Sanofi	  
(France)	  
46.4	   15.1	   6.5	   14.0	  
GlaxoSmithKline	  
(UK)	  
39.9	   12.5	   5.3	   13.2	  
Abbot	  Laboratories	  
(USA)	  
39.9	   8.8	   4.2	   10.5	  
AstraZeneca	  
(UK	  &	  Sweden)	  
28.0	   8.15	   5.2	   18.6	  
Bayer	  HealthCare	  
(Germany)	  
24.3	   4.2	   4.0	   16.5	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*The	  numbers	  in	  brackets	  are	  for	  the	  pharmaceutical	  segment	  as	  Johnson	  &	  Johnson	  manufactures	  mainly	  non-­‐pharmaceutical	  products	  but	  is	  still	  considered	  as	  the	  biggest	  pharmaceutical	  company	  in	  the	  world.	  	  	  In	  2011	  the	  global	  pharmaceutical	  spending	  was	  $956	  billion,	  a	  45%	  increase	  from	  2006	  (IFPMA,	  2012).	  It	  is	  predicted	  to	  continue	  to	  grow	  and	  reach	  $1,175-­‐1,205	  billion	  by	  2016	  due	  to	  an	  increased	  demand	  from	  the	  leading	  emerging	  countries	  (figure	  2).	  The	  branded,	  patent	  protected	  products,	  which	  are	  the	  main	  income	  source	  for	  the	  research-­‐based	  pharmaceutical	  companies,	  accounted	  for	  two-­‐thirds	  of	  2011’s	  total	  market	  value.	  	  
	  
Figure	  2.	  The	  global	  pharmaceutical	  spending	  in	  2006,	  2011	  and	  2016	  outlook	  (source:	  IFPMA	  facts	  and	  figures	  2012,	  p.	  52).	  
	  
	  Looking	  at	  the	  number	  of	  new	  molecular	  entities	  (NME)	  approved	  by	  FDA’s	  Center	  for	  Drug	  Evaluation	  and	  Research	  (CDER)	  from	  1990	  to	  2012,	  we	  can	  clearly	  see	  a	  downward	  trend	  in	  the	  last	  22	  years	  (figure	  3),	  which	  has	  repeatedly	  been	  issued	  as	  one	  of	  the	  main	  challenges	  for	  the	  industry.	  Given	  the	  fact	  that	  a	  patent	  protected	  drug	  has	  the	  potential	  to	  become	  a	  blockbuster	  and	  generate	  billions	  of	  dollars	  in	  annual	  revenues	  for	  the	  pharmaceutical	  company	  shows	  how	  critical	  innovation	  is	  for	  the	  survival	  of	  the	  research-­‐based	  companies.	  As	  fewer	  drugs	  are	  entering	  the	  market,	  several	  blockbusters	  have	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lost	  their	  patents	  or	  are	  facing	  a	  near	  in	  the	  future	  patent	  loss.	  Pfizer,	  for	  example	  saw	  the	  patent	  expire	  for	  their	  cholesterol-­‐reducing	  drug	  Lipitor®,	  the	  best-­‐selling	  drug	  in	  the	  history	  of	  pharmaceuticals.	  In	  2011,	  which	  was	  the	  final	  year	  with	  patent	  protection	  in	  the	  USA	  (it	  had	  lost	  its	  patent	  in	  a	  few	  other	  countries	  a	  year	  before),	  the	  drug	  accounted	  for	  approximately	  14%	  of	  Pfizer’s	  total	  revenues	  (Pfizer,	  2012).	  With	  $125	  billion	  in	  total	  sales	  before	  generic	  market	  entry,	  the	  exclusivity	  loss	  had	  a	  significant	  impact	  on	  the	  company.	  Due	  to	  generics	  cost	  at	  least	  20-­‐70%	  less	  in	  most	  markets	  (FTC,	  2012),	  the	  branded	  product’s	  sales	  drop	  drastically.	  	  
	  
Figure	  3.	  NMEs	  approved	  between	  1990-­‐2012	  (biologics	  excluded)	  by	  FDA	  (source:	  FDA’s	  summary	  of	  New	  Drug	  Application	  Approvals	  &	  Receipts).	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Germany,	  Europe’s	  biggest	  pharmaceutical	  spender,	  had	  a	  generous	  free	  pricing	  market	  between	  1996	  to	  2009,	  but	  joined	  other	  Western	  European	  countries	  in	  the	  stricter	  approach	  of	  pricing	  and	  reimbursement,	  with	  no	  thoughts	  of	  returning	  to	  the	  previous	  system	  (Henschke,	  Sundmacher	  and	  Busse,	  2012).	  The	  objective	  of	  the	  generous	  pricing	  was	  to	  encourage	  R&D	  productivity	  so	  more	  promising	  drug	  candidates	  would	  enter	  the	  market	  without	  the	  risk	  of	  having	  their	  value	  downgraded	  during	  the	  development	  process.	  This	  idea	  of	  excluding	  patented	  pharmaceuticals	  from	  price	  regulation,	  led	  eventually	  to	  the	  launch	  of	  several	  me-­‐too	  drugs	  that	  did	  not	  have	  any	  clear	  additional	  value	  in	  the	  safety	  or	  efficacy	  aspect,	  but	  a	  higher	  price	  label	  for	  a	  similar,	  already	  existing	  product	  (Henschke,	  Sundmacher	  and	  Busse,	  2012).	  While	  in	  most	  cases	  similar,	  some	  of	  the	  me-­‐too	  drugs	  have	  shown	  significant	  superior	  properties	  compared	  to	  competitors’	  products.	  Pfizer’s	  Lipitor®,	  mentioned	  earlier,	  is	  one	  example.	  Not	  being	  the	  first	  drug	  approved	  market	  authorization	  in	  that	  particular	  therapeutic	  cluster;	  it	  suddenly	  became	  the	  drug	  of	  choice	  for	  its	  indication.	  Thus	  me-­‐too	  drugs	  being	  rejected	  in	  an	  early	  stage	  may	  sometimes	  be	  a	  huge	  loss	  for	  the	  sector’s	  stakeholders,	  but	  encouraged	  by	  the	  payers,	  which	  we	  will	  discuss	  in	  the	  next	  section.	  	  
Investigating	  The	  Pipelines	  To	  further	  understand	  how	  today’s	  trend	  is	  among	  the	  aforementioned	  pharmaceutical	  companies;	  a	  review	  of	  their	  current	  drug	  pipelines	  was	  made.	  Abbott	  Laboratories	  was	  not	  included	  in	  the	  review	  due	  to	  lack	  of	  reliable	  source	  for	  their	  R&D	  product	  pipeline.	  The	  results	  are	  shown	  in	  table	  3.	  As	  can	  been	  seen,	  the	  top	  five	  therapeutic	  areas	  of	  choice	  by	  the	  investigated	  firms	  are	  oncology,	  followed	  by	  central	  nervous	  system	  (CNS),	  immunology-­‐inflammation,	  respiratory	  and	  vaccines.	  Rare	  diseases,	  which	  were	  previously	  neglected	  in	  the	  industry,	  considered	  costly,	  risky	  and	  mostly	  non-­‐profitable,	  have	  currently	  14	  R&D-­‐projects.	  Companies	  invested	  heavily	  in	  the	  cardiovascular	  area	  during	  the	  90’s,	  but	  the	  interest	  has	  decreased	  as	  other	  diseases	  and	  difficulties	  have	  changed	  the	  path	  for	  R&D-­‐investments.	  The	  characteristics	  of	  the	  drugs	  have	  definitely	  changed,	  which	  do	  not	  come	  as	  a	  surprise	  when	  the	  industry	  tries	  to	  adapt	  to	  new	  conditions	  and	  demands.	  Specific	  targets	  are	  chosen	  and	  the	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presence	  of	  me-­‐too	  drugs	  is	  limited	  for	  example.	  These	  changes	  correctly	  provide	  the	  market	  a	  higher	  potential	  of	  new	  breakthrough	  medicines.	  However,	  the	  outcome	  of	  these	  new	  products,	  such	  as	  availability,	  shortage	  of	  other	  drugs	  and	  payers	  willingness	  to	  reimburse	  would	  show	  a	  better	  proof	  of	  correct	  management	  by	  the	  stakeholders	  or	  just	  a	  temporary	  solution.	  	  	  
Table	  3.	  An	  estimate	  of	  current	  drug	  pipeline	  for	  nine	  of	  the	  biggest	  pharmaceutical	  companies	  (Abbott	  Laboratories	  excluded)	  in	  the	  world	  (source:	  drug	  pipeline	  of	  each	  company	  in	  December	  2013	  according	  to	  statements	  on	  their	  websites).	  	  
	  
	  
Therapeutic	  Area	   Number	  of	  
Projects	  
Oncology	   184	  
CNS	   58	  
Immunology-­‐inflammation	   53	  
Respiratory	   49	  
Vaccines	   42	  
Cardiovascular/Hematology	   37	  
Anti-­‐infective	   35	  
Diabetes	   18	  
Rare	  Diseases	   14	  
Ophthalmic	   9	  
Hormone-­‐control	   9	  
Metabolism	   6	  
Muscular-­‐skeletal	   5	  
Genitourinary	   4	  
Renal	   3	  
Obesity	   3	  
Gastro-­‐intestinal	   1	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Method	  
To	  understand	  how	  the	  FDA	  could	  influence	  the	  ongoing	  trend	  from	  their	  point	  of	  view,	  interviews	  were	  made	  with	  current	  FDA	  employees.	  Five	  persons	  in	  total	  were	  interviewed.	  Due	  to	  the	  FDA	  is	  based	  in	  Bethesda,	  MD,	  USA;	  it	  was	  impossible	  to	  do	  face-­‐to-­‐face	  interviews.	  Neither	  was	  it	  possible	  to	  do	  voice-­‐over	  IP	  (e.g.	  Skype)	  interviews	  as	  too	  many	  of	  them	  had	  heavy	  schedules.	  	  	  It	  is	  in	  our	  interest	  to	  see	  on	  which	  level	  the	  organization’s	  awareness	  about	  pricing	  and	  reimbursement	  impact	  and	  the	  character	  of	  the	  new	  drug	  application	  (NDA)	  they	  receive	  and	  process	  is,	  from	  its	  own	  employees’	  perspective.	  	  	  A	  primarily	  qualitative	  research	  approach	  (Silverman,	  2001)	  was	  used	  to	  gain	  in-­‐depth	  insights	  into	  the	  specific	  problem,	  but	  also	  a	  way	  of	  generating	  ideas	  for	  future	  research.	  In	  this	  way,	  we	  avoided	  and	  did	  not	  downplay	  statistical	  techniques	  (Silverman,	  2001).	  A	  survey	  with	  mostly	  open-­‐ended	  questions	  was	  sent	  thru	  e-­‐mail	  to	  the	  employees,	  which	  they	  had	  approximately	  two	  weeks	  to	  answer	  (Dec	  17	  –	  Jan	  2).	  If	  the	  answers	  were	  perceived	  as	  incomplete,	  i.e.	  misunderstanding	  of	  the	  question	  had	  occurred,	  s/he	  was	  contacted	  again	  for	  further	  explanations	  so	  the	  answer(s)	  would	  be	  correctly	  answered.	  By	  using	  a	  qualitative	  approach,	  the	  underlying	  factors	  would	  be	  identified	  (Silverman	  2001).	  The	  number	  of	  interviewees	  was	  another	  reason	  the	  qualitative	  method	  was	  chosen	  over	  the	  quantitative.	  According	  to	  Silverman	  (2001),	  qualitative	  research’s	  interview	  method	  consists	  of	  open-­‐ended	  questions	  to	  small	  samples.	  Because	  of	  the	  nature	  of	  the	  questions,	  which	  potentially	  could	  produce	  answers	  in	  conflict	  with	  the	  employer’s,	  all	  the	  respondents	  were	  guaranteed	  anonymity.	  	  Due	  to	  the	  interview	  is	  web-­‐based,	  the	  method	  does	  not	  allow	  one	  to	  understand	  the	  organization	  of	  talk	  and	  body	  movements	  (Silverman,	  2001,	  p.	  19).	  It	  makes	  it	  also	  difficult	  to	  add	  follow-­‐up	  questions	  to	  some	  answers	  that	  may	  be	  spontaneous,	  which	  is	  hard	  to	  see	  in	  the	  absence	  of	  a	  face-­‐to-­‐face	  interview	  (Silverman,	  2001,	  p.	  19).	  However,	  a	  positive	  aspect	  is	  that	  it	  limits	  the	  interviewer	  to	  lead	  the	  interviewees	  in	  a	  desired	  direction	  that	  would	  bring	  a	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subjective,	  rather	  than	  an	  objective	  view	  (Johnson,	  2014).	  The	  subject	  could,	  as	  mentioned	  before,	  be	  viewed	  as	  sensitive	  for	  the	  respondents.	  By	  having	  a	  web-­‐based	  survey	  the	  view	  of	  human	  behavior	  was	  avoided	  (Johnson,	  2014),	  which	  could	  have	  caused	  inconvenience.	  The	  research	  ethic	  of	  guarantee	  of	  anonymity	  could	  give	  the	  employees	  a	  fair	  opportunity	  to	  answer	  as	  honest	  as	  possible	  (Decision	  Analyst,	  2014).	  Furthermore,	  the	  answers	  written	  are	  each	  respondent’s	  own	  opinion	  and	  should	  not	  be	  seen	  as	  official	  FDA	  statements	  by	  the	  reader.	  	  A	  few	  background	  questions	  (see	  appendix)	  were	  given	  to	  the	  interviewees,	  such	  as	  gender,	  age,	  education	  background,	  role	  and	  years	  in	  the	  FDA.	  This	  made	  it	  possible	  to	  distinguish	  or	  link	  the	  employees’	  opinions	  if	  certain	  trends	  were	  shown	  in	  the	  results.	  Later	  in	  the	  analysis	  and	  discussion	  sections,	  the	  current	  literature	  and	  the	  nine	  pharmaceutical	  companies’	  drug	  pipelines	  are	  compared	  with	  the	  respondents’	  opinions	  and	  ideas.	  	  After	  all	  five	  interviewees	  had	  responded	  to	  the	  questions,	  patterns	  in	  the	  produced	  answers,	  but	  also	  any	  differences	  and	  similarities	  between	  the	  respondents	  were	  observed.	  	  
	  
Empirical	  Data	  All	  five	  interviewees	  are	  employed	  at	  the	  CDER	  division	  of	  the	  FDA.	  Their	  main	  role	  is	  to	  review	  and	  evaluate	  data	  for	  drug	  approval,	  submitted	  by	  pharmaceutical	  companies.	  Their	  strong	  educational	  background,	  with	  Ph.Ds.	  in	  relevant	  field	  also	  shows	  how	  competent	  the	  agency’s	  employees	  are.	  Their	  experience	  within	  the	  FDA	  spans	  from	  1	  year	  to	  5	  years,	  together	  a	  total	  of	  12	  years.	  They	  have	  also	  had	  previous	  interaction	  in	  their	  careers	  with	  the	  pharmaceutical	  industry	  and	  regulatory	  agencies,	  prior	  to	  the	  FDA.	  	  	  	  Unfortunately,	  one	  of	  the	  respondents	  did	  not	  provide	  full	  answers	  to	  most	  of	  the	  questions.	  The	  main	  reason	  was	  his	  official	  position	  in	  FDA,	  but	  also	  lack	  of	  knowledge.	  Although	  the	  survey	  was	  designed	  to	  minimize	  suspiciousness	  and	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create	  comfort,	  the	  nature	  of	  the	  questions	  could	  be	  perceived	  as	  sensitive,	  thus	  this	  did	  not	  come	  as	  a	  surprise.	  	  	  When	  asked	  what	  they	  think	  can	  be	  underlying	  factors	  behind	  the	  changes	  in	  the	  industry,	  two	  of	  the	  respondents	  mentioned	  the	  evolving	  science.	  Three	  of	  them,	  explained	  the	  profit	  driven	  phenomena	  the	  companies	  have	  to	  follow	  which	  appear	  in	  different	  shapes;	  biologic	  drugs	  that	  are	  hard	  to	  make	  generic	  of;	  outsourcing	  to	  developing	  countries	  such	  as	  China	  and	  India;	  development	  costs	  and	  limited	  R&D	  breakthroughs.	  The	  explanation	  to	  why	  the	  drugs	  today	  differ	  from	  the	  ones	  that	  were	  introduced	  10-­‐20	  years	  ago	  is	  that	  the	  industry	  focuses	  on	  different	  therapeutic	  areas	  from	  time	  to	  time;	  therapies	  for	  harder	  targets	  are	  being	  developed	  (i.e.	  more	  biologic,	  individualized	  and	  pediatric	  drugs).	  None	  of	  them	  saw	  differences	  with	  previous	  and	  current	  drugs	  with	  respect	  to	  the	  safety	  and	  efficacy	  issues.	  	  Three	  of	  the	  employees	  were	  able	  to	  respond	  to	  the	  question	  about	  the	  financial	  model	  (i.e.	  the	  agency	  is	  financed	  partly	  by	  user	  fees)	  and	  how	  it	  may	  affect	  the	  organization.	  Overall	  they	  did	  not	  see	  any	  conflict	  of	  interest.	  In	  the	  follow-­‐up	  question,	  which	  asked	  for	  their	  opinion	  regarding	  the	  relationship	  between	  the	  agency	  and	  the	  industry,	  the	  responses	  could	  be	  summarized	  with	  the	  words	  cooperative,	  coexistence	  and	  co-­‐development.	  	  The	  recent	  switch	  from	  blockbuster	  drugs	  to	  drugs	  targeting	  small	  populations	  that	  cost	  multifold	  more	  and	  the	  consequences	  this	  may	  have	  for	  the	  stakeholders,	  was	  apparent	  among	  three	  of	  the	  respondents,	  but	  also	  understandable.	  According	  to	  them,	  the	  drug	  price	  per	  capita	  for	  the	  orphan	  products	  is	  still	  comparable	  with	  blockbuster	  drugs,	  and	  the	  public	  must	  understand	  that	  the	  industry	  is	  not	  a	  charity	  organization.	  This	  may	  lead	  to	  limited	  access	  to	  such	  extremely	  expensive	  drugs,	  but	  in	  fact	  a	  better	  scenario	  than	  if	  they	  would	  never	  had	  been	  developed.	  Additionally,	  although	  the	  FDA	  cannot	  regulate	  the	  price	  directly,	  they	  actively	  work	  to	  reduce	  the	  costs	  for	  these	  drugs	  in	  their	  own	  way,	  e.g.	  by	  speeding	  up	  the	  review	  time	  and	  waive	  the	  user	  fee.	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  On	  the	  question	  if	  the	  agency	  should,	  except	  the	  drug	  and	  safety,	  also	  consider	  the	  cost	  of	  the	  product	  when	  reviewing	  new	  drug	  applications,	  none	  of	  the	  respondents	  agreed	  with	  that.	  FDA	  manage	  the	  scientific	  part	  of	  the	  drug	  development,	  but	  can	  affect	  the	  financial	  part,	  as	  mentioned	  previously,	  by	  extending	  exclusivity	  rights,	  user	  fee	  etc.	  One	  of	  the	  respondents	  underlined	  the	  fact	  that	  any	  drug	  can	  be	  approved	  as	  long	  as	  it	  is	  safe	  and	  effective,	  not	  taking	  into	  account	  the	  price	  tag	  of	  the	  product.	  	  Further,	  when	  the	  interviewees	  were	  asked	  about	  their	  thoughts	  on	  the	  lack	  of	  innovation	  and	  increased	  global	  pharmaceutical	  spending	  being	  unsustainable	  for	  the	  market,	  and	  FDA’s	  role	  in	  this	  issue,	  some	  interesting	  answers	  were	  given.	  Three	  of	  the	  respondents	  said	  that	  the	  FDA	  has	  taken	  initiatives	  that	  may	  eventually	  evade	  this	  problem,	  which	  also	  is	  the	  agency’s	  main	  mission.	  One	  respondent	  claimed	  that	  the	  presumption	  was	  false,	  due	  to	  that	  generic	  drugs	  occupy	  80%	  of	  the	  market,	  and	  the	  financial	  part	  is	  determined	  by	  politics,	  not	  by	  the	  agency.	  Another	  respondent	  explained	  how	  FDA	  is	  at	  the	  end	  of	  the	  drug	  development	  pipeline;	  how	  government	  should	  not	  regulate	  the	  economic	  part,	  but	  let	  the	  market	  take	  care	  of	  it.	  The	  need	  for	  science	  progress	  was	  also,	  and	  obviously,	  of	  importance.	  	  When	  asked	  if	  they	  saw	  any	  link	  between	  the	  increasing	  global	  pricing	  and	  reimbursement	  regulations	  affecting	  the	  drug	  innovation,	  the	  opinions	  varied.	  One	  answered	  that	  it	  was	  a	  question	  for	  the	  payers.	  Two	  other	  answers	  were	  given,	  where	  the	  first	  one	  claimed	  that	  the	  companies’	  revenues	  had	  not	  declined	  and	  the	  pipeline	  problems	  could	  be	  referred	  to	  changing	  science.	  The	  second	  answer	  brought	  up	  the	  fact	  that	  the	  whole	  business	  is	  highly	  risky,	  with	  long	  cycles	  but	  also	  high	  return.	  With	  less	  return,	  the	  industry	  would	  face	  less	  investment.	  	  	  In	  one	  question,	  the	  current	  product	  pipeline	  (table	  3)	  was	  exemplified	  and	  the	  interviewees	  were	  asked	  what	  could	  be	  behind	  this	  trend,	  looking	  at	  the	  key	  stakeholders.	  Interestingly,	  one	  respondent’s	  simple	  answer	  was	  the	  business	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model	  the	  pharmaceutical	  industry	  is	  based	  on	  i.e.	  unmet	  medical	  need	  that	  need	  to	  be	  filled	  by	  sufficiently	  evolved	  science	  and	  an	  existing	  market.	  Another	  respondent	  also	  came	  across	  the	  unmet	  medical	  need	  and	  market	  part,	  but	  also	  explained	  the	  scientific	  part	  in	  terms	  of	  difficulties	  in	  current	  available	  treatments	  and	  success	  rate.	  Two	  other	  respondents	  also	  mentioned	  the	  important	  role	  of	  the	  market.	  One	  of	  them	  pointed	  at	  the	  fact	  that	  the	  agency	  has	  beneficial	  regulation	  roles	  for	  tropical	  diseases	  such	  as	  malaria,	  but	  as	  the	  market	  is	  almost	  non-­‐existent	  in	  the	  U.S.	  and	  western	  world	  in	  general,	  they	  do	  not	  receive	  any	  submissions	  for	  this	  certain	  disease,	  and	  confirms	  that	  the	  FDA	  has	  limited	  impact	  on	  the	  companies’	  preferences.	  	  	  Only	  two	  of	  the	  respondents	  answered	  on	  the	  question	  regarding	  the	  increasing	  issue	  of	  drug	  shortages,	  especially	  of	  older	  generic	  drugs.	  One	  answered	  instantly	  on	  profit	  and	  the	  low	  interest	  on	  manufacturing	  drugs	  where	  the	  profit	  is	  low	  and	  the	  competition	  high.	  The	  second	  respondent	  mentioned	  that	  the	  FDA	  is	  taking	  steps	  to	  regulate	  this	  problem.	  The	  industry	  is	  for	  example	  obligated	  to	  inform	  the	  agency	  if	  they	  have	  plans	  to	  change	  their	  product	  line	  or	  decrease	  the	  production	  of	  a	  specific	  product.	  Thereby	  the	  FDA	  can	  proactively	  prevent	  drug	  shortages.	  	  In	  the	  final	  question,	  where	  the	  interviewees	  were	  asked	  about	  their	  ideas	  and	  suggestions	  on	  how	  the	  FDA	  could	  improve	  the	  innovation	  climate	  in	  the	  industry,	  two	  respondents	  underlined	  that	  the	  FDA	  promotes	  and	  welcomes	  a	  climate	  of	  innovation	  for	  the	  whole	  industry.	  One	  respondent	  specifically	  issued	  the	  safety	  challenge	  as	  the	  most	  costly	  and	  low-­‐efficient	  part	  in	  the	  drug	  development	  process.	  He	  suggests	  that	  if	  the	  agency	  lowered	  the	  safety	  bar	  upon	  approval	  and	  moved	  the	  main	  part	  to	  post-­‐market,	  the	  result	  could	  eventually	  accelerate	  drug	  innovation	  and	  development.	  	  
Analysis	  Throughout	  the	  answers,	  the	  scientific	  focus	  is	  clearly	  obvious.	  The	  FDA	  is	  highly	  specialized	  in	  this	  field.	  Hirsch	  and	  Whisler	  (1982)	  and	  March	  and	  March	  (1977)	  studies	  showed	  how	  the	  hiring	  process	  in	  some	  organizations	  ended	  with	  the	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recruitment	  of	  people	  that	  were	  indistinguishable.	  The	  more	  top-­‐level	  the	  less	  separable	  were	  the	  candidates,	  which	  was	  typical	  for	  normative	  isomorphism.	  The	  adaptation	  to	  the	  changing	  market	  rules	  have	  been	  challenging	  as	  could	  be	  read	  in	  the	  literature	  overview.	  Changing	  science	  and	  harder	  targets	  are	  two	  reasons	  why,	  which	  the	  respondents	  and	  the	  literature	  both	  referred	  to.	  Looking	  at	  the	  increasing	  global	  pharmaceutical	  spending,	  the	  majority	  of	  the	  respondents	  gave	  a	  clear	  answer	  that	  the	  agency	  is	  working	  towards	  a	  more	  sustainable	  structure,	  i.e.	  more	  isomorphism.	  The	  statement	  from	  one	  respondent	  that	  generic	  drugs	  have	  80%	  stands	  in	  conflict	  with	  the	  literature	  that	  states	  that	  branded	  products	  accounted	  for	  nearly	  two-­‐thirds	  of	  the	  global	  market	  in	  2011	  (IFPMA,	  2012).	  He	  may	  have	  referred	  to	  the	  local	  U.S.,	  and	  not	  the	  global	  market.	  	  Lack	  of	  innovation	  being	  a	  main	  challenge	  comes	  repeatedly	  in	  mind	  for	  the	  interviewees.	  One	  employee	  opposed	  the	  fact	  of	  the	  falling	  trend	  in	  revenues	  for	  the	  companies,	  which	  they	  compensate	  with	  e.g.	  M&A	  and	  cutting	  staff.	  The	  R&D-­‐	  investments	  as	  percentage	  of	  annual	  sales	  are	  currently	  unchanged	  but	  could	  as	  another	  respondent	  underlined,	  that	  a	  decline	  in	  revenues	  would	  eventually	  lead	  to	  less	  investment,	  hence	  less	  innovation.	  The	  answers	  on	  the	  question	  of	  drug	  shortage	  were	  consistent	  with	  Jensen	  and	  Rappaport	  (2010)	  article	  about	  the	  low	  priority	  of	  older	  generic	  drugs	  and	  the	  increasing	  profit	  driven	  thinking.	  Further,	  regarding	  the	  formal	  structure,	  none	  of	  the	  employees	  agreed	  on	  FDA	  taking	  a	  bigger	  responsibility	  in	  influencing	  a	  healthy	  price	  level	  of	  the	  drugs,	  thus	  become	  more	  isomorphic	  to	  its	  environment.	  	  	  The	  respondents	  explained	  the	  current	  product	  pipeline	  as	  a	  result	  of	  the	  market.	  The	  high	  success	  rate,	  unmet	  medical	  need	  and	  difficulties	  in	  current	  available	  treatments	  were	  all	  reasons	  for	  the	  companies	  focused	  therapeutic	  areas.	  Friederiszick,	  et	  al.	  (2009)	  also	  came	  up	  with	  this	  conclusion.	  The	  profit	  driven	  phenomena	  leading	  to	  R&D	  investments	  in	  diseases	  that	  affect	  small	  populations	  compared	  to	  10-­‐20	  years	  ago	  when	  the	  industry’s	  R&D	  investments	  were	  in	  the	  psychiatric	  and	  cardiovascular	  diseases,	  show	  how	  the	  cycle	  changes	  from	  time	  to	  time,	  where	  regulations	  for	  example	  orphan	  drugs	  (Reaves,	  2003)	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may	  have	  been	  involved	  to	  influence.	  Still	  the	  drug	  price	  per	  capita	  is	  quite	  the	  same	  between	  the	  cheaper	  blockbuster	  drugs	  and	  the	  expensive	  specialized	  drugs,	  which	  one	  of	  the	  interviewees	  was	  concerned	  about	  that	  it	  could	  lead	  to	  limited	  access.	  	  	  Cost-­‐effectiveness	  studies	  have	  been	  suggested	  to	  improve	  the	  management	  of	  drug	  innovation	  and	  spending	  issues	  that	  the	  sector	  is	  suffering	  from.	  There	  were	  no	  suggestions	  of	  this	  by	  the	  respondents.	  However,	  one	  employee	  had	  an	  idea	  of	  decreasing	  the	  safety	  bar,	  which	  eventually	  would	  decrease	  the	  cost	  of	  the	  development	  cost	  significantly.	  	  
Discussion	  Meyer	  and	  Rowan	  (1977)	  repeatedly	  mention	  how	  important	  it	  is	  with	  isomorphism	  for	  organizations	  success	  and	  survival.	  They	  also	  mention	  that	  powerful	  organizations	  force	  their	  relational	  networks	  to	  adapt	  to	  their	  structures	  and	  relations.	  The	  pharmaceutical	  industry,	  as	  well	  as	  the	  FDA	  are	  both	  well	  known	  for	  having	  huge	  influence	  on	  their	  environment.	  The	  respondents	  described	  the	  relationship	  in	  positive	  terms	  although	  the	  never-­‐ending	  debate	  on	  who	  influence	  whom	  the	  most	  continues.	  Some	  critics	  say	  that	  the	  industry	  has	  the	  edge;	  given	  the	  fact	  that	  42%	  of	  CDER	  was	  financed	  by	  industry	  fees	  in	  2007	  (Stone,	  2012),	  with	  no	  signs	  of	  decreasing.	  Phillips	  and	  Zuckerman	  (2001)	  argued	  about	  high-­‐status	  players	  being	  able	  to	  deviate	  from	  the	  norm	  thanks	  to	  reputational	  capital.	  But	  at	  the	  same	  time,	  the	  FDA	  is	  considered	  as	  much	  more	  transparent	  organization	  than	  the	  pharmaceutical	  companies.	  Powell	  and	  DiMaggio	  (1991,	  p.	  74)	  argue	  that	  organizations	  can	  greatly	  resist	  the	  demands	  of	  organizations	  that	  they	  are	  not	  dependent	  on.	  This	  can	  be	  one	  of	  the	  reasons	  to	  why	  a	  clear	  isomorphic	  change	  has	  not	  been	  noticed	  in	  an	  independent	  organization	  as	  the	  FDA,	  although	  the	  market	  rules	  have	  changed	  drastically.	  The	  two	  authors	  continue	  with	  the	  hypothesis	  that	  when	  the	  relationship	  between	  means	  and	  ends	  is	  uncertain,	  the	  more	  an	  organization	  will	  model	  itself	  after	  organizations	  that	  it	  considers	  as	  successful.	  This	  can	  be	  an	  explanation	  to	  why	  pharmaceutical	  companies	  put	  their	  R&D	  budgets	  on	  certain	  therapeutic	  areas	  from	  time	  to	  time.	  This	  mimetic	  trend	  also	  limits	  the	  number	  of	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targets	  for	  the	  benefit	  of	  the	  patient,	  but	  as	  a	  profit	  driven	  industry,	  it	  is	  almost	  impossible	  to	  influence	  the	  preferences.	  More	  regulations	  can	  be	  a	  solution	  to	  manage	  this	  problem,	  but	  it	  would	  eventually	  lead	  to	  less	  return	  and	  an	  ineffective	  incentive	  for	  continuous	  innovation.	  	  	  	  	  Powell	  and	  DiMaggio	  (1991,	  p.	  76)	  also	  write	  about	  how	  more	  interactions	  between	  organization	  and	  agencies	  of	  the	  state	  could	  result	  in	  increased	  isomorphism	  in	  the	  field	  as	  a	  whole.	  Here	  we	  see	  again	  the	  need	  for	  better	  communication	  between	  the	  main	  actors	  in	  the	  sector.	  As	  for	  now,	  it	  is	  quite	  hard	  to	  say	  which	  part,	  the	  agency,	  or	  the	  industry,	  is	  submitting	  and	  becoming	  isomorphic	  to	  the	  other	  part.	  	  Previous	  research	  covering	  the	  specific	  link	  discussed	  is	  limited,	  in	  spite	  of	  the	  fact	  that	  it	  may	  have	  a	  critical	  role	  in	  spending	  and	  the	  number	  and	  characteristics	  of	  drugs	  launched	  in	  the	  future	  market,	  partial	  explanations	  behind	  the	  trend	  can	  be	  found	  in	  current	  literature.	  Kanavos	  and	  Reinhardt	  (2003)	  discuss	  how	  policymakers,	  by	  subjecting	  similar	  products	  (the	  so	  called	  me-­‐too	  drugs)	  to	  pricing	  pressure	  from	  reference	  pricing,	  they	  can	  shift	  the	  R&D-­‐investments	  made	  by	  the	  pharmaceutical	  companies	  to	  more	  useful	  innovative	  drugs.	  Thereby	  safety	  and	  efficacy	  are	  not	  the	  only	  aspects	  concerned	  when	  reviewing	  a	  new	  product	  for	  the	  stakeholders,	  but	  also	  clinical	  and	  cost	  effectiveness	  are	  included	  in	  the	  social	  rate	  of	  return.	  	  	  To	  innovate	  pharmaceuticals,	  not	  just	  of	  financial	  importance	  for	  its	  owner,	  but	  also	  for	  public	  interest,	  can	  by	  viewers	  be	  seen	  as	  a	  win-­‐win	  situation.	  In	  the	  past,	  the	  industry	  had	  a	  strong	  focus	  on	  developing	  drugs	  in	  the	  same	  therapeutic	  cluster,	  as	  they	  had	  a	  high	  potential	  to	  become	  blockbusters	  and	  well	  received	  by	  the	  payers	  (E.CA	  Compact,	  2012).	  As	  the	  rules	  have	  changed,	  drug	  manufacturers	  have	  for	  example	  been	  encouraged	  to	  innovate	  orphan	  drugs	  used	  to	  treat	  rare	  diseases	  (Reaves,	  2003).	  But	  at	  the	  same	  time,	  more	  and	  more	  reports	  regarding	  drug	  shortage	  of	  off-­‐patent	  substances	  give	  a	  hint	  of	  the	  consequences	  of	  price	  regulations.	  Jensen	  and	  Rappaport	  (2010)	  discuss	  the	  sudden	  shortage	  of	  the	  drug	  propofol,	  a	  fast-­‐onset,	  shortacting,	  sedative-­‐
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hypnotic	  agent	  that	  healthcare	  professionals	  have	  come	  to	  rely	  on	  as	  standard	  of	  care.	  Propofol	  is	  an	  off-­‐patent	  drug	  that	  has	  been	  on	  the	  market	  for	  years.	  There	  are	  a	  limited	  number	  of	  manufacturers	  of	  this	  product	  due	  to	  complexity	  in	  the	  production	  process.	  However,	  the	  low	  profit	  margin	  could	  be	  a	  more	  causing	  factor	  than	  the	  two	  previously	  mentioned	  as	  pharmaceutical	  companies	  may	  favor	  newer,	  more	  profitable	  products	  in	  their	  production	  lines.	  This	  dilemma,	  where	  well-­‐proven	  and	  relatively	  cheap,	  traditional	  drugs	  sometimes	  have	  a	  lower	  priority	  among	  the	  manufacturers,	  and	  which	  drug	  regulatory	  agencies	  arguably	  cannot	  affect	  strongly,	  shows	  how	  harmful	  drug	  shortage	  can	  be	  for	  the	  healthcare	  system.	  As	  discussed	  earlier,	  new	  drugs	  enjoy	  patent	  protection	  for	  a	  certain	  time.	  During	  this	  time	  the	  company	  behind	  the	  drug	  must	  be	  compensated	  for	  all	  the	  R&D	  costs	  made.	  Price	  regulations	  may	  therefore	  be	  an	  effective	  way	  for	  the	  payers	  to	  keep	  the	  expenditure	  within	  a	  healthy	  range	  and	  still	  promote	  innovation.	  There	  are	  however	  different	  views	  regarding	  this	  subject.	  In	  a	  study	  of	  the	  German	  market,	  Henschke,	  Sundmacher	  and	  Busse	  (2012),	  described	  how	  the	  2011	  Act	  for	  Restructuring	  the	  Pharmaceutical	  Market	  in	  Statutory	  Health	  Insurance	  (AMNOG)	  created	  pharmaceutical	  cost	  containment	  and	  an	  expected	  	  €2	  billion	  in	  health	  insurance	  cost	  savings.	  Prior	  to	  that,	  the	  manufacturer	  set	  the	  patented	  drug’s	  price.	  The	  purpose	  of	  the	  act	  was	  to	  negotiate	  (i.e.	  regulate)	  the	  price	  that	  reflects	  the	  additional	  benefit	  of	  the	  pharmaceutical	  compared	  to	  the	  appropriate	  competitor.	  Although	  applied	  in	  several	  European	  countries	  as	  Germany	  is	  used	  as	  a	  reference	  for	  pharmaceutical	  price	  setting,	  Abbott	  (1994)	  questions	  this	  type	  of	  price	  regulation	  for	  being	  effective.	  	  The	  main	  conflict	  it	  may	  cause	  is	  the	  introductory	  price,	  which	  Henschke,	  Sundmacher	  and	  Busse	  (2012)	  also	  mentioned	  briefly.	  Here,	  Abbott	  clearly	  showed	  how	  pharmaceutical	  companies	  in	  a	  regulated	  market	  launch	  prices	  50%	  higher	  than	  in	  an	  unregulated	  market.	  After	  seven	  years	  the	  unregulated	  price	  exceeds	  the	  regulated.	  The	  overall	  result	  depends	  on	  the	  social	  and	  corporate	  discount	  rates,	  thus	  making	  the	  question	  of	  pricing	  even	  more	  complex.	  Abbott	  also	  wrote	  how	  price	  and	  reimbursement	  regulation	  in	  general	  provides	  the	  incentive	  to	  produce	  efficiently,	  which	  in	  this	  case	  would	  result	  in	  more	  useful	  innovative	  drugs.	  However,	  he	  underlines	  that	  this	  is	  more	  realistic	  in	  stable	  markets	  where	  both	  the	  cost	  and	  the	  demand	  are	  constant	  over	  
	   	   	   26	  
time,	  which	  is	  contrary	  to	  the	  pharmaceutical	  market	  with	  high	  and	  volatile	  demand	  (e.g.	  pandemics)	  and	  short	  product	  life	  cycles.	  	  Friederiszick,	  et	  al.	  (2009),	  get	  close	  on	  pricing	  and	  reimbursement	  regulation	  versus	  innovation.	  They	  see	  a	  trend	  where	  the	  health	  authorities	  are	  moving	  to	  cost-­‐effectiveness	  considerations	  rather	  than	  the	  cost-­‐cutting	  policies	  they	  previously	  had.	  With	  this	  regulatory	  system	  the	  R&D	  direction	  of	  the	  pharmaceutical	  firms	  would	  likely	  be	  to	  first-­‐in-­‐class	  drugs	  as	  they	  have	  the	  potential	  of	  becoming	  highly	  recognized.	  As	  a	  consequence,	  firms	  would	  cancel	  projects	  where	  they	  see	  the	  risk	  of	  ending	  up	  as	  a	  later-­‐in-­‐class	  drug.	  Because	  of	  this,	  the	  diversity	  within	  certain	  future	  classes	  could	  be	  limited	  until	  generic	  competition	  is	  allowed.	  This	  is	  probably	  the	  case	  for	  markets	  that	  apply	  IRP.	  Looking	  at	  EBP,	  they	  see	  the	  risk	  of	  not	  launching	  new	  products	  in	  countries	  with	  low	  willingness	  to	  pay	  and	  focusing	  R&D	  investments	  on	  countries	  with	  high	  willingness	  to	  pay	  as	  the	  return	  would	  most	  likely	  be	  significantly	  higher.	  Regarding	  value-­‐based	  pricing,	  pharmacoeconomic	  assessment	  may	  be	  viewed	  as	  the	  most	  fair	  method	  of	  pricing	  and	  reimbursement,	  but	  difficulties	  arise	  on	  how	  to	  measure	  the	  benefits	  generated	  to	  the	  society	  at	  large,	  and	  not	  only	  to	  individual	  users.	  Furthermore,	  the	  shifting	  innovation	  model	  to	  more	  tailored	  drugs	  (i.e.	  drugs	  that	  treat	  rare	  diseases	  or	  only	  a	  part	  of	  the	  population	  suffering	  from	  a	  disease)	  has	  indeed	  been	  a	  result	  of	  decreasing	  returns	  and	  to	  some	  degree	  difficulty	  to	  discover	  new	  drugs	  that	  target	  large	  and	  heterogeneous	  primary	  care	  patients.	  But	  these	  so	  called	  personalized	  drugs	  can	  cost	  several	  hundreds	  of	  thousand	  dollars	  per	  treated	  patient	  and	  year	  compared	  to	  perhaps	  a	  couple	  of	  thousand	  of	  dollars	  for	  the	  ones	  that	  are	  for	  primary	  care	  patients.	  The	  R&D	  spending	  is	  still	  high	  for	  drugs	  aimed	  for	  small	  patient	  populations	  and	  therefore	  the	  price	  will	  be	  considerably	  higher	  for	  the	  product.	  The	  cost-­‐effectiveness	  importance	  has	  made	  firms	  conducting	  pharmacoeconomic	  studies	  on	  their	  products.	  To	  eliminate	  the	  risk	  of	  bias	  and	  ensure	  substantial	  evidence	  for	  claims,	  the	  FDA	  has	  drafted	  guidelines	  for	  such	  practices,	  but	  in	  reality	  there	  are	  no	  standards	  for	  valuing	  health	  benefits.	  Usually,	  the	  perspective	  of	  the	  user	  decides	  whether	  or	  not	  a	  drug	  is	  cost-­‐effective.	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Historically	  being	  an	  organization	  overseeing	  drugs’	  safety	  and	  efficacy,	  Neumann,	  Zinner	  and	  Paltiel	  (1996)	  criticize	  the	  agency’s	  lack	  of	  competence	  in	  the	  area	  of	  cost-­‐effectiveness	  and	  consequently	  how	  they	  manage	  it.	  The	  authors	  mention	  an	  example	  of	  a	  drug	  that	  was	  over	  700%	  more	  expensive	  than	  its	  competitor’s,	  but	  reduced	  the	  risk	  of	  mortality	  with	  only	  1%.	  Still	  it	  had	  70%	  of	  the	  market	  share.	  There	  is	  another	  example	  of	  a	  drug	  with	  an	  initial	  price	  tag	  4900%	  higher	  than	  an	  alternative	  that	  has	  been	  compounded	  by	  pharmacies	  for	  years	  (Gleason,	  2013).	  Although	  the	  company	  lowered	  the	  price	  and	  eventually	  filed	  for	  bankruptcy,	  it	  raises	  question	  marks	  on	  how	  it	  was	  allowed	  market	  entry	  and	  potentially	  create	  uncertainty	  among	  physicians	  on	  which	  drug	  they	  should	  prescribe.	  Additionally,	  a	  recently	  published	  article	  (Sullivan,	  et	  al.,	  2011)	  discusses	  how	  cancer	  care	  costs	  grow	  and	  why	  affordability,	  but	  also	  accessibility	  and	  value	  should	  be	  confronted.	  This	  report	  brings	  back	  the	  issue	  of	  old,	  well-­‐proven,	  but	  not	  so	  profitable	  drugs	  being	  phased	  out	  for	  the	  benefit	  of	  newer,	  multifold	  expensive	  drugs.	  The	  suspiciousness	  that	  exists	  especially	  between	  the	  drug	  regulatory	  agency	  and	  the	  companies	  does	  not	  facilitate	  the	  problems	  with	  innovation	  and	  spending.	  The	  struggle	  between	  the	  formal	  structure	  of	  the	  FDA,	  with	  an	  intrinsic	  unwillingness	  to	  adapt	  too	  much	  to	  the	  environment,	  thus	  increase	  the	  cooperation,	  overseeing	  an	  industry	  with	  profit	  driven	  companies	  that	  not	  always	  have	  the	  patient’s	  health	  as	  main	  interest,	  continues.	  One	  can	  wonder	  how	  the	  reaction	  would	  be	  if	  the	  FDA	  one	  day	  took	  into	  consideration	  the	  price	  of	  a	  new	  drug	  that	  would	  be	  90%	  as	  good	  as	  the	  safest	  and	  most	  effective	  one	  in	  the	  current	  market	  (i.e.	  first	  line	  treatment),	  but	  only	  10%	  of	  the	  cost?	  	  
	  
Conclusion	  and	  Future	  Research	  This	  thesis	  has	  tried	  to	  investigate	  how	  the	  need	  of	  better	  management	  of	  pharmaceutical	  spending	  and	  drug	  innovation,	  probably	  is	  being	  partly	  limited	  by	  the	  formal	  structure	  of	  a	  highly	  respected	  and	  influential	  drug	  regulatory.	  In	  an	  extremely	  complex	  and	  internationalized	  business,	  challenges	  arise	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Appendix	  
	  
Interview	  questions	  	  
1.	  Age	  	  If	  you	  do	  not	  want	  to	  specify	  age,	  please	  type	  in	  an	  age	  interval	  e.g.	  30-­‐39,	  40-­‐49	  etc.	  
	  
2.	  Gender	  	  
	  
3.	  What	  is	  your	  education	  background?	  	  Please	  specify,	  e.g.	  PhD	  in	  pharmacology,	  MSc	  in	  Chemistry	  etc.	  	  
4.	  What	  is	  your	  role/title	  in	  the	  agency?	  	  
5.	  How	  many	  years	  have	  you	  worked	  in	  the	  FDA?	  	  
	  
6.	  The	  pharmaceutical	  industry	  has	  seen	  several	  changes	  in	  the	  last	  couple	  
of	  years.	  What	  underlying	  factors	  do	  you	  think	  are	  behind	  these	  changes?	  	  
	  
7.	  How	  do	  you	  think	  the	  current	  financial	  model	  (PDUFA)	  for	  parts	  of	  the	  
agency	  is	  perceived	  by	  the	  public?	  	  	  
8.	  In	  your	  opinion,	  what	  is	  the	  nature	  of	  the	  relationship	  between	  the	  
Agency	  and	  the	  regulated	  industry?	  	  
9.	  In	  your	  opinion,	  are	  there	  any	  differences	  in	  the	  types	  of	  drugs	  that	  are	  
being	  approved	  now,	  10,	  and	  20	  years	  ago?	  
	  
10.	  Currently	  companies	  have	  switched	  from	  developing	  “blockbuster”	  
products	  to	  niche	  products	  targeting	  small	  populations.	  The	  cost	  for	  such	  
products	  are	  often	  multifold	  higher	  compared	  to	  products	  aimed	  toward	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larger	  patient	  populations.	  In	  your	  opinion,	  what	  are	  the	  major	  issues	  with	  
increased	  cost	  for	  such	  products	  for	  patients,	  doctors,	  and	  insurance	  
institutions	  (government	  or	  private)?	  
	  
11.	  Do	  you	  feel	  that	  the	  agency	  should	  consider	  the	  cost	  of	  the	  product	  
when	  reviewing	  new	  drug	  applications?	  
	  
12.	  The	  pharmaceutical	  market	  experience	  increased	  spending	  because	  of	  
aging	  population	  and	  developing	  countries	  investing	  in	  their	  healthcare	  
systems.	  But	  at	  the	  same	  time	  fewer	  drugs	  are	  granted	  market	  entry.	  There	  
have	  been	  discussions	  how	  this	  trend	  is	  not	  sustainable.	  What	  changes	  do	  
you	  think	  are	  needed	  for	  a	  more	  effective	  sector	  regarding	  innovation	  and	  
cost	  containment?	  Do	  you	  think	  FDA	  could	  contribute	  to	  a	  more	  sustainable	  
development?	  	  
	  
13.	  How	  would	  you	  say	  the	  increasing	  global	  pricing	  &	  reimbursement	  
regulations	  affect	  the	  drug	  innovation	  for	  the	  research-­‐based	  
pharmaceutical	  companies?	  Could	  they	  be	  linked	  in	  your	  opinion?	  	  
	  
14.	  Looking	  at	  the	  current	  drug	  pipeline	  in	  nine	  of	  the	  biggest	  
pharmaceutical	  companies,	  we	  can	  see	  that	  the	  therapeutic	  areas	  targeted	  
are	  1.	  Oncology	  2.	  CNS	  3.	  Immunology-­‐inflammation	  4.	  Respiratory	  5.	  
Vaccines.	  Which	  factors	  do	  you	  think	  could	  be	  behind	  this	  trend	  looking	  at	  
the	  key	  stakeholders	  e.g.	  the	  innovating	  pharmaceutical	  companies	  and	  the	  
regulatory	  agencies?	  
	  
15.	  Drug-­‐shortages	  have	  repeatedly	  been	  reported,	  especially	  on	  older	  
generic	  drugs.	  Why	  has	  this	  problem	  become	  recurring	  in	  this	  highly	  
regulated	  area	  covered	  by	  the	  FDA?	  	  
16.	  Finally,	  having	  answered	  the	  previous	  questions,	  do	  you	  have	  any	  
ideas/suggestions	  on	  how	  the	  FDA	  could	  improve	  the	  innovation	  climate	  in	  
the	  pharmaceutical	  industry?	  
